Last Update 01 Apr 26

NPCE: Higher Margin Conviction And Reaffirmed Guidance Will Support More Optimistic Outlook

Analysts have modestly increased their price target on NeuroPace by $1, citing refreshed assumptions around long term profit margins and a slightly higher future P/E multiple.

Analyst Commentary

Bullish Takeaways

Bullish analysts see room for long term margin improvement, which supports their willingness to apply a slightly higher future P/E multiple in their models.
The recent $1 adjustment to the price target reflects refreshed assumptions around profitability, suggesting that execution on cost discipline and operating leverage is an important part of the thesis.
Optimistic views center on NeuroPace’s ability to convert its current business model into sustainable earnings power over time, which they feel justifies a premium valuation versus prior assumptions.
Some bullish analysts highlight that even modest tweaks to profit margin expectations can meaningfully influence fair value estimates when combined with a re-rated P/E framework.

Bearish Takeaways

More cautious analysts may question whether the improved long term margin assumptions are realistic, given execution risks around scaling the business and controlling costs.
There is sensitivity to the use of a higher future P/E multiple, with concerns that valuation could be vulnerable if earnings growth or profitability do not match these refreshed expectations.
The modest size of the price target change can be read as a signal that, while the outlook has been fine tuned, upside may depend heavily on consistent execution against profitability goals.
Cautious analysts might emphasize that any setback in achieving targeted margins could lead to a reset in both earnings estimates and the valuation multiple currently being used.

What's in the News

NeuroPace reiterated earnings guidance for first quarter 2026, with total revenue expected between US$21 million and US$22 million (company guidance).
The company also reiterated full year 2026 total revenue guidance of US$98 million to US$100 million (company guidance).
Management linked the full year 2026 revenue range to underlying RNS business growth of 20% to 22% compared with full year 2025 (company guidance).
Earlier guidance for first quarter 2026 outlined the same revenue range of US$21 million to US$22 million, along with full year 2026 revenue of US$98 million to US$100 million tied to 20% to 22% growth in core RNS revenue versus preliminary unaudited 2025 RNS revenue (company guidance).

Valuation Changes

Fair Value: Model fair value remains unchanged at $19.88 per share.
Discount Rate: The discount rate has risen slightly from 8.01% to 8.02%, indicating a marginally higher required return in the model.
Revenue Growth: The revenue growth assumption is essentially unchanged at 15.39%.
Net Profit Margin: The long term profit margin assumption has eased slightly from 13.36% to 13.08%.
Future P/E: The future P/E multiple has risen slightly from 43.9x to 44.9x, reflecting a modest adjustment to the valuation multiple applied to earnings.

0 views

Key Takeaways

Expanding presence in epilepsy centers and Project CARE may significantly boost revenue by increasing market penetration and service delivery.
AI-enhancements and clinical program advancements promise operational efficiency, new revenue streams, and improved financial performance.
NeuroPace's growth strategy relies on ambitious expansions, new product success, and increased prescriber engagement, yet faces risks from resource strain and market adoption challenges.

Catalysts

About NeuroPace

Operates as a medical device company in the United States.What are the underlying business or industry changes driving this perspective?

Expanding adoption and utilization within Level 4 comprehensive epilepsy centers could significantly increase revenue by tapping into a $2 billion annual core market opportunity.
Project CARE aims to expand site of service delivery and has begun contributing to revenue growth; doubling implants and referrals can further drive revenue increases.
Advancing key clinical development programs to expand indications of use for the RNS System suggests potential new revenue streams and market expansion, positively impacting future earnings.
Introduction of AI-enabled software tools and next-generation platform improvements might enhance operational efficiency and patient outcomes, potentially boosting both revenue and net margins.
Strengthened balance sheet post-public offering supports strategic growth initiatives and operating expansions, aiming for cash flow breakeven and improved earnings.

NeuroPace Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming NeuroPace's revenue will grow by 15.4% annually over the next 3 years.
Analysts are not forecasting that NeuroPace will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate NeuroPace's profit margin will increase from -21.5% to the average US Medical Equipment industry of 13.1% in 3 years.
If NeuroPace's profit margin were to converge on the industry average, you could expect earnings to reach $20.1 million (and earnings per share of $0.55) by about April 2029, up from -$21.5 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 45.4x on those 2029 earnings, up from -20.6x today. This future PE is greater than the current PE for the US Medical Equipment industry at 27.5x.
Analysts expect the number of shares outstanding to grow by 2.65% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.02%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

NeuroPace's rapid expansion strategy at Level 4 comprehensive epilepsy centers and outside of them with Project CARE depends on significant increases in implants and referrals, which might strain their resources and potentially affect revenue if expected growth doesn't materialize as projected.
The company's 2025 revenue guidance is heavily reliant on the success of new product offerings and indications, such as the NAUTILUS pivotal study and pediatric RNS indications. Regulatory or clinical trial setbacks could delay these expansions and impact forecasted revenue growth.
While gross margins are currently healthy, potential fluctuations in the mix of distributed product lines, like DIXI Medical, which carry lower margins, could pressure overall gross margins, impacting profitability.
The company's reliance on increasing prescriber numbers and direct-to-consumer marketing for revenue growth might incur higher-than-anticipated expenses, affecting their net income and ability to achieve cash flow breakeven.
NeuroPace's significant investments in AI-enabled software tools and new technologies aim for long-term gains, but if deployment or adoption is slower than expected, it could impact short-to-medium-term earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $19.88 for NeuroPace based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $22.0, and the most bearish reporting a price target of just $18.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $153.6 million, earnings will come to $20.1 million, and it would be trading on a PE ratio of 45.4x, assuming you use a discount rate of 8.0%.
Given the current share price of $13.15, the analyst price target of $19.88 is 33.8% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on NeuroPace?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Expanding Level 4 Epilepsy Centers Will Unlock Future Potential